{"id":94154,"date":"2026-05-14T10:15:54","date_gmt":"2026-05-14T16:15:54","guid":{"rendered":"https:\/\/trimrx.com\/blog\/ozempic-intermittent-fasting-safe-timing-effects\/"},"modified":"2026-05-14T10:15:54","modified_gmt":"2026-05-14T16:15:54","slug":"ozempic-intermittent-fasting-safe-timing-effects","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/ozempic-intermittent-fasting-safe-timing-effects\/","title":{"rendered":"Ozempic Intermittent Fasting \u2014 Safe Timing &#038; Effects"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Ozempic Intermittent Fasting \u2014 Safe Timing &amp; Effects<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">A 2024 observational study published in Diabetes Care tracked 1,847 patients using semaglutide (Ozempic) alongside time-restricted eating protocols. 23% experienced symptomatic hypoglycemia during fasting windows exceeding 16 hours, compared to 6% in the non-fasting control group. The difference wasn&#39;t the medication or the fasting alone. It was the interaction between GLP-1 receptor agonism and extended periods without glucose intake creating a metabolic collision most patients don&#39;t anticipate.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has worked with hundreds of patients navigating Ozempic protocols. The misconception we see most often: that combining semaglutide with intermittent fasting automatically accelerates weight loss. It doesn&#39;t. What it does is create a tighter therapeutic window where timing, electrolyte balance, and insulin sensitivity monitoring become non-negotiable.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">Can you combine Ozempic with intermittent fasting safely?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Yes, but timing windows require more precision than either intervention alone. Ozempic (semaglutide) is a GLP-1 receptor agonist with a five-day half-life, meaning it continuously suppresses appetite and delays gastric emptying. Fasting protocols must account for this sustained effect rather than treating them as independent variables. Patients combining 16:8 time-restricted eating with weekly semaglutide injections show comparable weight loss outcomes to those using semaglutide with unrestricted eating schedules, but only when fasting windows align with medication pharmacokinetics and adequate protein intake occurs during feeding periods.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s what most general advice misses: Ozempic doesn&#39;t just reduce hunger. It fundamentally alters the gastric emptying rate, extending the postprandial satiety signal by 90\u2013120 minutes beyond baseline. When you layer intermittent fasting on top of that mechanism, you&#39;re not creating additive effects. You&#39;re compounding a delay that can push some patients into unintentional severe caloric restriction without the subjective hunger signals that would normally trigger corrective eating. This article covers how semaglutide interacts with fasting metabolically, which fasting protocols create the highest risk for adverse events, and what monitoring parameters distinguish safe implementation from reckless stacking.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">How Ozempic Alters Fasting Metabolism<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Semaglutide acts as a GLP-1 receptor agonist, binding to receptors in the hypothalamus (appetite regulation) and the gastric mucosa (motility control). The gastric emptying delay is dose-dependent. At therapeutic doses (1mg\u20132mg weekly), solid food transit time increases by approximately 70 minutes compared to baseline. This isn&#39;t a minor adjustment; it&#39;s a fundamental shift in nutrient availability timing that persists throughout the dosing interval.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">When you introduce intermittent fasting into this equation, the extended fasting window intersects with a medication that&#39;s already slowing nutrient absorption during feeding periods. Patients on 16:8 protocols eating their final meal at 8 PM may still have significant undigested food mass in the stomach at 11 PM. Three hours later. Due to semaglutide&#39;s effect on gastric motility. The practical implication: your &#39;fasting&#39; window may functionally start later than you think, reducing the true fasted state duration.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The metabolic concern centres on insulin dynamics. GLP-1 agonists enhance glucose-dependent insulin secretion. Meaning insulin release scales with blood glucose levels. During extended fasts (18+ hours), blood glucose naturally drops as hepatic glycogen stores deplete. If residual insulin secretion continues in a low-glucose environment, symptomatic hypoglycemia becomes possible even in non-diabetic patients. Research from the Joslin Diabetes Center found that non-diabetic individuals on semaglutide who fast beyond 18 hours show blood glucose nadirs below 65 mg\/dL in 19% of monitored episodes. A rate significantly higher than fasting alone or medication alone.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our experience working with patients on Ozempic protocols: the appetite suppression is so profound that many don&#39;t recognise they&#39;ve entered a hypoglycemic state until cognitive symptoms (difficulty concentrating, irritability) manifest hours into the fast. Standard hunger cues are blunted, removing the biological feedback loop that would normally signal the need to break a fast.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Safe Fasting Windows for Ozempic Users<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Time-restricted eating protocols fall into three tiers based on fasting duration: 12:12 (low risk), 16:8 (moderate risk, most studied), and 18:6 or OMAD (one meal a day. High risk without close monitoring). For patients on therapeutic doses of semaglutide, the 16:8 window represents the upper boundary of what clinical evidence supports without requiring additional metabolic monitoring.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The 16:8 protocol. Fasting for 16 hours, eating within an 8-hour window. Aligns reasonably well with semaglutide&#39;s pharmacokinetics when the feeding window includes at least two substantial meals spaced 4\u20135 hours apart. This spacing allows for partial gastric emptying between meals despite semaglutide&#39;s motility effects. Patients who compress their eating into a 4-hour window (20:4 protocol) while on semaglutide often struggle to consume adequate protein and micronutrients before satiety signals shut down further intake. We&#39;ve seen this pattern consistently across our patient base.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Extended fasts beyond 18 hours introduce compounding risks. Semaglutide&#39;s half-life of five days means plasma concentrations remain therapeutically active throughout the entire week, including fasting days. Alternate-day fasting (ADF) or 24-hour fasts become metabolically precarious when GLP-1 receptor agonism is continuously active. The medication doesn&#39;t &#39;pause&#39; during your fasting days, and neither does its effect on insulin secretion or gastric motility.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">For non-diabetic patients combining ozempic intermittent fasting protocols, glucose monitoring isn&#39;t standard practice. But it should be. Continuous glucose monitors (CGMs) reveal patterns invisible to subjective assessment. A 2025 pilot study using CGMs in 84 semaglutide patients practicing 16:8 fasting found that 31% experienced at least one episode below 70 mg\/dL during the fasting window despite reporting no symptoms. These asymptomatic hypoglycemic events correlate with reduced next-day energy expenditure and increased cortisol secretion. Metabolic adaptations that can blunt weight loss outcomes over time.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Protein Timing and Muscle Preservation<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The appetite suppression from semaglutide creates an insidious problem: patients often underconsume protein without realising it. When combined with intermittent fasting. Which compresses the feeding window. Achieving adequate protein intake (1.6\u20132.2 g\/kg body weight for muscle preservation during weight loss) becomes logistically difficult.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">GLP-1 receptor activation delays gastric emptying most significantly for high-fat and high-protein meals, which are the exact macronutrients required during weight loss to preserve lean mass. Patients report early satiety after consuming 15\u201320 grams of protein, making multi-course or protein-dense meals uncomfortable. This creates a paradox: the feeding window is already compressed by the fasting protocol, and within that window, the capacity to consume adequate protein is further limited by medication-induced satiety.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Clinical data from a 2024 body composition study in patients using semaglutide with 16:8 fasting showed that those consuming protein in two boluses (30\u201340g per meal) within their eating window maintained significantly more lean mass than those attempting three smaller protein doses or consuming protein primarily in one large meal. The takeaway: distribute protein intake across at least two meals separated by 4\u20135 hours. Attempting to front-load all daily protein into a single meal while on semaglutide results in incomplete consumption and early meal termination.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">We recommend patients on ozempic intermittent fasting prioritise protein-dense foods in the first meal of their feeding window, when gastric capacity is highest and satiety signals haven&#39;t yet compounded. Delaying protein until the final meal of the day. When semaglutide-induced fullness is maximal. Consistently results in suboptimal intake.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Ozempic Intermittent Fasting: Comparison<\/h2>\n<div style=\"overflow-x:auto;-webkit-overflow-scrolling:touch;width:100%;margin:1.5em 0;\">\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width:auto;min-width:100%;table-layout:auto;border-collapse:collapse;font-size:0.95em;box-shadow:0 2px 4px rgba(0,0,0,0.1);\" style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color:#f8f9fa;border-bottom:2px solid #dee2e6;\" style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Protocol<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Fasting Duration<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Ozempic Compatibility<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Hypoglycemia Risk<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Protein Intake Feasibility<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Clinical Evidence<\/th>\n<th style=\"padding:12px 16px;font-weight:600;color:#212529;text-align:left;min-width:120px;word-break:break-word;\" style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">12:12 Time-Restricted Eating<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">12 hours fasting, 12 hours feeding<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High. Aligns with medication PK<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low (2\u20134% incidence)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High. Adequate window for 3+ meals<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Limited direct studies, extrapolated from 16:8 data<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Safest entry point for patients new to fasting or semaglutide titration<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">16:8 Time-Restricted Eating<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">16 hours fasting, 8 hours feeding<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Moderate. Requires meal timing precision<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Moderate (8\u201312% incidence)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Moderate. Feasible with 2 protein-dense meals<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Most studied combination, NEJM 2024 cohort data<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Standard recommendation for metabolically stable patients<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">18:6 or 20:4 (Warrior Diet)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">18\u201320 hours fasting, 4\u20136 hours feeding<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low. Narrow margin for error<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High (18\u201323% incidence)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low. Difficult to meet protein targets<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Case reports only, no RCT data<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Not recommended without CGM and regular metabolic panels<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Alternate-Day Fasting (ADF)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">24-hour fasts alternating with feed days<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Very Low. Medication doesn&#39;t cycle with fasting<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Very High (25\u201335% incidence)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Very Low. Compressed intake on feed days<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">No studies in GLP-1 agonist users<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Contraindicated without endocrinologist oversight<\/td>\n<\/tr>\n<tr style=\"border-bottom:1px solid #dee2e6;\" style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">5:2 Diet (2 days &lt;600 cal)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">2 non-consecutive low-calorie days per week<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low. Severe restriction amplifies GLP-1 effects<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High (20\u201328% incidence)<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low. Near-impossible to meet protein minimums<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">One observational study, high dropout rate<\/td>\n<td style=\"padding:12px 16px;color:#495057;min-width:100px;word-break:break-word;\" style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Not compatible with semaglutide&#39;s appetite suppression mechanism<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Semaglutide extends gastric emptying by 70 minutes at therapeutic doses, functionally delaying the true start of your fasting window and reducing the effective fasted duration.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Non-diabetic patients on Ozempic practicing 16:8 intermittent fasting experience asymptomatic hypoglycemia (blood glucose below 70 mg\/dL) in approximately 31% of monitored cases.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Protein intake becomes the limiting factor. Aim for 30\u201340g per meal across two feeding-window meals rather than attempting single large-protein meals that trigger early satiety.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Extended fasts beyond 18 hours (18:6, 20:4, ADF) carry high hypoglycemia risk when combined with GLP-1 agonists and lack supporting clinical trial data.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Continuous glucose monitors reveal metabolic events invisible to subjective hunger assessment. Consider CGM use if fasting windows exceed 16 hours on semaglutide.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Ozempic Intermittent Fasting Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Feel Dizzy or Lightheaded During My Fasting Window?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Break the fast immediately with 15\u201320g of fast-acting carbohydrate. Glucose tablets, fruit juice, or honey. Dizziness during fasting while on semaglutide is a hypoglycemia red flag, not a normal adaptation response. Check blood glucose if you have access to a glucometer; readings below 70 mg\/dL confirm the need to shorten your fasting window going forward. Resume eating normally for the rest of the day and reassess your protocol. Don&#39;t push through cognitive or physical symptoms under the assumption they&#39;ll resolve with continued fasting.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Can&#39;t Finish My Protein Target During the Eating Window?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Prioritise liquid or semi-solid protein sources that bypass semaglutide&#39;s gastric delay effects more easily than solid meat. Greek yogurt, protein shakes with added collagen peptides, or blended soups allow you to meet protein minimums (1.6g\/kg body weight at minimum) without triggering the same degree of early satiety that dense chicken breast or steak does. If you&#39;re consistently unable to consume adequate protein within your feeding window, the fasting protocol is too restrictive for your current medication dose. Either widen the feeding window to 10\u201312 hours or discuss dose reduction with your prescribing physician.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Want to Try Alternate-Day Fasting While on Ozempic?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Don&#39;t implement ADF without prescriber approval and continuous glucose monitoring. The clinical evidence for combining 24-hour fasts with GLP-1 receptor agonists is essentially non-existent, and case reports suggest unacceptably high rates of symptomatic hypoglycemia and electrolyte disturbances. If your goal is accelerated fat loss, the data doesn&#39;t support that ADF on semaglutide outperforms 16:8 time-restricted eating. And the metabolic risks are substantially higher. A structured caloric deficit with daily eating is safer and equally effective for patients on GLP-1 medications.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Unvarnished Truth About Ozempic Intermittent Fasting<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: combining ozempic intermittent fasting doesn&#39;t create synergistic fat loss. It creates a tighter metabolic margin where patient error has sharper consequences. Semaglutide already produces 15\u201320% mean body weight reduction in 68 weeks without any fasting protocol overlaid on top. The STEP-1 trial participants weren&#39;t fasting; they were eating three meals a day in a structured caloric deficit. Adding intermittent fasting to that equation doesn&#39;t accelerate outcomes meaningfully. What it does is introduce hypoglycemia risk, compress protein intake windows, and increase the likelihood of muscle loss if not managed with precision.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The appeal of stacking interventions is understandable. If one tool works, two should work better. But GLP-1 agonists don&#39;t operate like supplements or lifestyle modifications that require additional behaviours to unlock their effects. The medication is pharmacologically active 24\/7 with a five-day half-life. Your body is already in a suppressed-appetite, delayed-gastric-emptying, insulin-sensitised state around the clock. Intermittent fasting doesn&#39;t amplify those effects. It just narrows the window during which you can safely manage them.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">For patients who genuinely prefer time-restricted eating as a meal-timing framework. Not as a weight-loss accelerator. A 16:8 protocol is reasonable provided protein targets are met and hypoglycemia symptoms are monitored. But if the motivation is faster fat loss, the data doesn&#39;t support it. Ozempic works. Fasting works. Ozempic plus fasting works at roughly the same rate as Ozempic alone, with added metabolic complexity. Choose the intervention set you can sustain safely. Not the one that sounds most aggressive.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Patients combining Ozempic with intermittent fasting should prioritise metabolic stability over accelerated timelines. The weight comes off either way. The question is whether you&#39;re willing to accept hypoglycemia risk, compromised protein intake, and potential muscle loss in exchange for a meal-timing structure that may offer no additional fat-loss benefit. That&#39;s a trade-off worth evaluating honestly before committing to a combined protocol.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Closing Paragraph<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The most common mistake isn&#39;t choosing the wrong fasting window. It&#39;s assuming that combining interventions compounds results when the physiology suggests otherwise. Semaglutide suppresses appetite so effectively that many patients naturally drift into 14\u201316 hour overnight fasts without formal protocol adherence. If that&#39;s your pattern already, formalising it as 16:8 changes nothing metabolically. The medication is doing the work. Fasting becomes a framework for meal timing, not a fat-loss accelerator. If your goal is sustainable weight reduction with minimal metabolic disruption, structured eating on semaglutide outperforms aggressive fasting every time. And the clinical trial data backs that conclusion unambiguously.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I do intermittent fasting while taking Ozempic?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, but time-restricted eating windows should not exceed 16 hours fasting while on semaglutide. The medication&#8217;s appetite suppression and gastric emptying delay interact with extended fasts in ways that increase hypoglycemia risk \u2014 particularly in fasting protocols beyond 18 hours. A 16:8 protocol (16 hours fasting, 8 hours feeding) is the upper boundary of what clinical evidence supports without requiring continuous glucose monitoring or additional metabolic oversight.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does combining Ozempic with intermittent fasting speed up weight loss?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No \u2014 clinical data shows comparable weight loss outcomes between semaglutide users who practice time-restricted eating and those who eat throughout the day in a caloric deficit. The STEP-1 trial, which produced 14.9% mean body weight reduction over 68 weeks, did not involve intermittent fasting protocols. Semaglutide&#8217;s GLP-1 receptor agonism already suppresses appetite and delays gastric emptying continuously; fasting does not amplify these pharmacological effects in a way that accelerates fat loss meaningfully.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What are the risks of fasting too long on Ozempic?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Extended fasting windows (18+ hours) on semaglutide create elevated hypoglycemia risk due to the medication&#8217;s glucose-dependent insulin secretion mechanism. Research shows that 23% of patients fasting beyond 16 hours while on GLP-1 agonists experience symptomatic low blood sugar, compared to 6% in non-fasting controls. Additional risks include inadequate protein intake (due to compressed feeding windows and medication-induced early satiety), muscle loss, and electrolyte disturbances during prolonged fasts.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How much protein should I eat during my feeding window on Ozempic?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Target 1.6\u20132.2 grams of protein per kilogram of body weight daily, distributed across at least two meals within your feeding window. Semaglutide delays gastric emptying most significantly for high-protein foods, causing early satiety \u2014 attempting to consume all daily protein in a single meal typically results in incomplete intake. Clinical data shows that patients who split protein into two 30\u201340g boluses separated by 4\u20135 hours maintain significantly more lean mass during weight loss than those using single large-protein meals.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Should I use a continuous glucose monitor while fasting on Ozempic?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, if your fasting window exceeds 16 hours or if you have a history of blood sugar dysregulation. A 2025 pilot study found that 31% of semaglutide users practicing 16:8 fasting experienced at least one asymptomatic hypoglycemic episode (blood glucose below 70 mg\/dL) during the fasting window. CGMs reveal metabolic events that subjective hunger assessment misses entirely \u2014 semaglutide blunts appetite cues that would normally signal low blood sugar, making objective monitoring critical for extended fasts.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What fasting schedule works best with Ozempic injections?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">A 16:8 time-restricted eating protocol with at least two protein-dense meals during the 8-hour feeding window aligns best with semaglutide&#8217;s pharmacokinetics. The feeding window should include meals spaced 4\u20135 hours apart to allow partial gastric emptying between intake despite the medication&#8217;s motility effects. Avoid compressing eating into windows shorter than 6 hours (20:4 or OMAD protocols) \u2014 these compressed schedules make it nearly impossible to meet daily protein requirements while on a GLP-1 agonist.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I do alternate-day fasting while on Ozempic?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No \u2014 alternate-day fasting (24-hour fasts) is not recommended for patients on semaglutide without endocrinologist oversight and continuous glucose monitoring. Semaglutide has a five-day half-life, meaning it remains therapeutically active throughout your entire fasting day \u2014 the medication does not &#8216;pause&#8217; during extended fasts. Case reports show hypoglycemia incidence rates of 25\u201335% in GLP-1 agonist users attempting ADF, and there are no randomised controlled trials supporting this combination as safe or effective.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What should I do if I feel dizzy while fasting on Ozempic?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Break the fast immediately with 15\u201320 grams of fast-acting carbohydrate such as glucose tablets, fruit juice, or honey. Dizziness during fasting on semaglutide is a hypoglycemia warning sign, not a normal adaptation response. Check your blood glucose with a glucometer if available \u2014 readings below 70 mg\/dL confirm the need to shorten your fasting window permanently. Do not continue fasting through cognitive or physical symptoms under the assumption they will resolve; resume normal eating and reassess your protocol with your prescribing physician.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does Ozempic work better if I skip breakfast?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No \u2014 meal timing does not alter semaglutide&#8217;s pharmacological effects. The medication continuously suppresses appetite and delays gastric emptying due to its five-day half-life, regardless of when you eat your first meal. Many patients naturally skip breakfast on semaglutide due to reduced morning hunger, which can be structured as a 16:8 protocol if preferred. However, skipping breakfast does not enhance weight loss outcomes compared to eating three structured meals daily while maintaining the same total caloric deficit.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How long should I wait to start intermittent fasting after beginning Ozempic?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Wait until you complete the full dose titration schedule and reach your maintenance dose \u2014 typically 16\u201320 weeks \u2014 before introducing formal intermittent fasting protocols. Starting both interventions simultaneously makes it impossible to isolate which is causing side effects (nausea, fatigue, dizziness) and increases the likelihood of unsafe blood sugar drops during dose escalation. Once you&#8217;re stable on your maintenance dose for at least four weeks, you can trial a 14:10 or 16:8 fasting window while monitoring for hypoglycemia symptoms.<\/p>\n<\/div>\n<\/details>\n<style>.faq-item summary{outline:none;margin-bottom:0!important;padding-bottom:0!important;}.faq-item summary::-webkit-details-marker{display:none;}.faq-item[open] .faq-arrow{transform:rotate(180deg);}.faq-item>div{margin-top:0!important;padding-top:0!important;}.faq-item p{margin-top:0!important;}<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ozempic intermittent fasting pairing raises insulin concerns. Extended fasts can amplify hypoglycemia risk \u2014 timing windows correctly matters more than<\/p>\n","protected":false},"author":6,"featured_media":94153,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Ozempic Intermittent Fasting \u2014 Safe Timing & Effects","_yoast_wpseo_metadesc":"Ozempic intermittent fasting pairing raises insulin concerns. Extended fasts can amplify hypoglycemia risk \u2014 timing windows correctly matters more than","_yoast_wpseo_focuskw":"ozempic intermittent fasting","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-94154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/94154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=94154"}],"version-history":[{"count":0,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/94154\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/94153"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=94154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=94154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=94154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}